降钙素原
急诊科
败血症
肝素
预测值
内科学
医学
多中心研究
部分凝血活酶时间
重症监护医学
蛋白质C
C反应蛋白
试验预测值
重症监护
危险分层
疾病严重程度
死亡率
胃肠病学
生物标志物
前瞻性队列研究
全身炎症反应综合征
风险因素
终点
感染性休克
严重败血症
作者
Konstantinos Katsaros,Georgios Renieris,Asimina Safarika,Evangelia-Maria Adami,Theologia Gkavogianni,George Giannikopoulos,Nicky Solomonidi,Stamatios Halvatzis,Ioannis M. Koutelidakis,Nikolaos Tsokos,Maroula Tritzali,Pantelis Koutoukas,Cristina Avgoustou,Anil Vasishta,Evangelos J. Giamarellos-Bourboulis
出处
期刊:Shock
[Lippincott Williams & Wilkins]
日期:2021-12-14
卷期号:57 (4): 518-525
被引量:41
标识
DOI:10.1097/shk.0000000000001900
摘要
ABSTRACT Background: The validation of new biomarkers for the diagnosis and risk stratification of patients with sepsis at an early point is essential for successful treatment. Recent publications prompted us to investigate of heparin binding protein (HBP) for the emergency department (ED) admissions. Materials and Methods: In this multicenter, cross-sectional study, HBP and procalcitonin (PCT) were measured within the first hour upon admission to the ED in plasma samples of 371 patients with signs of infection. Patients were classified into non-sepsis and sepsis by the Sepsis-3 definitions and were followed up for outcome. Results: HBP was significantly higher in patients with sepsis and was positively correlated to PCT and C-reactive protein, absolute neutrophil and monocyte counts, creatinine, bilirubin and lactate. Sensitivity, specificity, positive predictive value, and negative predictive value of HBP more than 19.8 ng/mL for the diagnosis of sepsis was 66.3%, 44.9%, 49.3%, and 62.2%, respectively; and for prediction of early death was 100%, 41.0%, 4.5%, and 100%, respectively. Single HBP and PCT could not predict 28-day mortality; this was performed with sensitivity, specificity, positive predictive value, and negative predictive value 44.8%, 81.8%, 17.3%, and 94.6% when used in combination. Conclusion: Admission HBP can be used as a tool for the early diagnosis of sepsis and for the risk of early death in the ED.
科研通智能强力驱动
Strongly Powered by AbleSci AI